Merck Cholesterol Franchise Will Decline In 2005

Merck predicts that Zocor franchise will lose about $750 mil. in sales during 2005, primarily due to European patent expirations. That will be partially offset by approximately $450 mil. in new income from Vytorin and Zetia through the joint venture with Schering-Plough.